• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Gastroenterology manifestations and COVID-19 outcomes: A meta-analysis of 25,252 cohorts among the first and second waves.胃肠病学表现和 COVID-19 结局:第一波和第二波中 25252 个队列的荟萃分析。
J Med Virol. 2021 May;93(5):2740-2768. doi: 10.1002/jmv.26836. Epub 2021 Feb 23.
2
Prevalence of Gastrointestinal Symptoms and Fecal Viral Shedding in Patients With Coronavirus Disease 2019: A Systematic Review and Meta-analysis.2019 年冠状病毒病患者的胃肠道症状和粪便病毒脱落的流行情况:系统评价和荟萃分析。
JAMA Netw Open. 2020 Jun 1;3(6):e2011335. doi: 10.1001/jamanetworkopen.2020.11335.
3
Prevalence and Persistent Shedding of Fecal SARS-CoV-2 RNA in Patients With COVID-19 Infection: A Systematic Review and Meta-analysis.新型冠状病毒感染患者粪便 SARS-CoV-2 RNA 的流行和持续脱落:系统评价和荟萃分析。
Clin Transl Gastroenterol. 2021 Apr 9;12(4):e00343. doi: 10.14309/ctg.0000000000000343.
4
Gastrointestinal Manifestations of SARS-CoV-2 Infection and Virus Load in Fecal Samples From a Hong Kong Cohort: Systematic Review and Meta-analysis.香港队列粪便样本中 SARS-CoV-2 感染的胃肠道表现及病毒载量:系统评价与荟萃分析
Gastroenterology. 2020 Jul;159(1):81-95. doi: 10.1053/j.gastro.2020.03.065. Epub 2020 Apr 3.
5
Digestive system involvement and clinical outcomes among COVID-19 patients: A retrospective cohort study from Qatar.卡塔尔一项回顾性队列研究:COVID-19 患者的消化系统受累及临床结局。
World J Gastroenterol. 2021 Dec 14;27(46):7995-8009. doi: 10.3748/wjg.v27.i46.7995.
6
Gastroenterological and hepatic manifestations of patients with COVID-19, prevalence, mortality by country, and intensive care admission rate: systematic review and meta-analysis.新型冠状病毒肺炎患者的胃肠及肝脏表现、各国患病率、病死率和重症监护病房入住率:系统评价和荟萃分析。
BMJ Open Gastroenterol. 2021 Mar;8(1). doi: 10.1136/bmjgast-2020-000571.
7
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.在基层医疗或医院门诊环境中,出现症状和体征来确定患者是否患有 COVID-19。
Cochrane Database Syst Rev. 2021 Feb 23;2(2):CD013665. doi: 10.1002/14651858.CD013665.pub2.
8
Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19.氯喹或羟氯喹预防和治疗 COVID-19。
Cochrane Database Syst Rev. 2021 Feb 12;2(2):CD013587. doi: 10.1002/14651858.CD013587.pub2.
9
Correlation of Gastrointestinal Symptoms at Initial Presentation with Clinical Outcomes in Hospitalized COVID-19 Patients: Results from a Large Health System in the Southern USA.美国南部某大型医疗体系中 COVID-19 住院患者初诊时胃肠道症状与临床结局的相关性:一项研究结果
Dig Dis Sci. 2022 Nov;67(11):5034-5043. doi: 10.1007/s10620-022-07384-0. Epub 2022 Feb 7.
10
Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.奈玛特韦片/利托那韦片组合包装用于 COVID-19 的预防和治疗。
Cochrane Database Syst Rev. 2022 Sep 20;9(9):CD015395. doi: 10.1002/14651858.CD015395.pub2.

引用本文的文献

1
Gastrointestinal Manifestation and In-hospital Mortality among End-Stage Renal Disease Patients with COVID-19: A Single-center Retrospective Cohort Study.新冠病毒肺炎终末期肾病患者的胃肠道表现及住院死亡率:一项单中心回顾性队列研究
Acta Med Philipp. 2025 Jul 15;59(9):83-89. doi: 10.47895/amp.vi0.9694. eCollection 2025.
2
COVID-19 risk stratification among older adults: a machine learning approach to identify personal and health-related risk factors.老年人中的新冠病毒疾病风险分层:一种用于识别个人及健康相关风险因素的机器学习方法
BMC Public Health. 2025 Jul 29;25(1):2577. doi: 10.1186/s12889-025-23862-2.
3
SARS-CoV-2 infectivity can be modulated through bacterial grooming of the glycocalyx.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的传染性可通过细菌对糖萼的修饰来调节。
mBio. 2025 Apr 9;16(4):e0401524. doi: 10.1128/mbio.04015-24. Epub 2025 Feb 25.
4
Acute Rectal Bleeding in a COVID-19 Patient: Chasing a Diagnosis.一名新冠肺炎患者的急性直肠出血:追寻诊断结果
Cureus. 2024 Aug 10;16(8):e66596. doi: 10.7759/cureus.66596. eCollection 2024 Aug.
5
Gastrointestinal bleeding in patients with COVID-19: an integrative review.新型冠状病毒肺炎患者的胃肠道出血:综合述评。
Rev Col Bras Cir. 2024 May 6;51:e20243600. doi: 10.1590/0100-6991e-20243600-en. eCollection 2024.
6
Inpatient outcomes of inflammatory bowel disease in hospitalized patients with COVID-19: analysis of a nationally representative sample.新冠肺炎住院患者中炎症性肠病的住院结局:一项全国代表性样本分析
Proc (Bayl Univ Med Cent). 2024 Feb 8;37(2):239-247. doi: 10.1080/08998280.2024.2303402. eCollection 2024.
7
Evolving Clinical Manifestations and Outcomes in COVID-19 Patients: A Comparative Analysis of SARS-CoV-2 Variant Waves in a Romanian Hospital Setting.新冠病毒感染患者不断演变的临床表现及预后:罗马尼亚一家医院环境中新冠病毒变异株浪潮的比较分析
Pathogens. 2023 Dec 14;12(12):1453. doi: 10.3390/pathogens12121453.
8
Associations between COVID-19 therapies and inpatient gastrointestinal bleeding: A multisite retrospective study.COVID-19 治疗药物与住院患者胃肠道出血的关联:一项多中心回顾性研究。
J Med Virol. 2023 Oct;95(10):e29100. doi: 10.1002/jmv.29100.
9
Excess Deaths of Gastrointestinal, Liver, and Pancreatic Diseases During the COVID-19 Pandemic in the United States.美国 COVID-19 大流行期间的胃肠道、肝脏和胰腺疾病超额死亡。
Int J Public Health. 2023 Aug 15;68:1606305. doi: 10.3389/ijph.2023.1606305. eCollection 2023.
10
A Systematic Review of the Prevalence of Persistent Gastrointestinal Symptoms and Incidence of New Gastrointestinal Illness after Acute SARS-CoV-2 Infection.急性 SARS-CoV-2 感染后持续性胃肠道症状的患病率和新发胃肠道疾病的发生率的系统评价。
Viruses. 2023 Jul 26;15(8):1625. doi: 10.3390/v15081625.

本文引用的文献

1
Decreased Case Fatality Rate of COVID-19 in the Second Wave: A study in 53 countries or regions.第二波 COVID-19 病例病死率降低:53 个国家和地区的研究。
Transbound Emerg Dis. 2021 Mar;68(2):213-215. doi: 10.1111/tbed.13819. Epub 2020 Sep 17.
2
AKI in Hospitalized Patients with COVID-19.COVID-19 住院患者中的急性肾损伤。
J Am Soc Nephrol. 2021 Jan;32(1):151-160. doi: 10.1681/ASN.2020050615. Epub 2020 Sep 3.
3
A Predictive Nomogram for Predicting Improved Clinical Outcome Probability in Patients with COVID-19 in Zhejiang Province, China.用于预测中国浙江省COVID-19患者临床结局改善概率的预测列线图。
Engineering (Beijing). 2022 Jan;8:122-129. doi: 10.1016/j.eng.2020.05.014. Epub 2020 Jun 6.
4
Clinical characteristics of patients diagnosed with COVID-19 in Beijing.北京新冠肺炎确诊患者的临床特征
Biosaf Health. 2020 Jun;2(2):104-111. doi: 10.1016/j.bsheal.2020.05.003. Epub 2020 May 12.
5
The characteristics and outcomes of 681 severe cases with COVID-19 in China.中国 681 例 COVID-19 重症病例的特征和结局。
J Crit Care. 2020 Dec;60:32-37. doi: 10.1016/j.jcrc.2020.07.003. Epub 2020 Jul 8.
6
A structural equation model to examine the clinical features of mild-to-moderate COVID-19: A multicenter Italian study.采用结构方程模型探究轻度至中度 COVID-19 的临床特征:一项多中心意大利研究。
J Med Virol. 2021 Feb;93(2):983-994. doi: 10.1002/jmv.26354. Epub 2020 Aug 2.
7
Clinical Characteristics and Predictors of Disease Progression in Severe Patients with COVID-19 Infection in Jiangsu Province, China: A Descriptive Study.江苏省 COVID-19 感染重症患者的临床特征及疾病进展预测因素:一项描述性研究。
Am J Med Sci. 2020 Aug;360(2):120-128. doi: 10.1016/j.amjms.2020.05.038. Epub 2020 Jun 1.
8
Emergence of European and North American mutant variants of SARS-CoV-2 in South-East Asia.东南亚出现欧洲和北美变异的 SARS-CoV-2 。
Transbound Emerg Dis. 2021 Mar;68(2):824-832. doi: 10.1111/tbed.13748. Epub 2020 Aug 9.
9
Gastrointestinal Complications in Critically Ill Patients With COVID-19.新型冠状病毒肺炎危重症患者的胃肠道并发症
Ann Surg. 2020 Aug;272(2):e61-e62. doi: 10.1097/SLA.0000000000004004.
10
Clinical characteristics of emergency surgery patients infected with coronavirus disease 2019 (COVID-19) pneumonia in Wuhan, China.中国武汉 2019 冠状病毒病(COVID-19)肺炎急诊手术患者的临床特征。
Surgery. 2020 Sep;168(3):398-403. doi: 10.1016/j.surg.2020.05.007. Epub 2020 May 19.

胃肠病学表现和 COVID-19 结局:第一波和第二波中 25252 个队列的荟萃分析。

Gastroenterology manifestations and COVID-19 outcomes: A meta-analysis of 25,252 cohorts among the first and second waves.

机构信息

Department of Biochemistry and Molecular Genetics, Faculty of Physical Therapy, Horus University - Egypt, New Damietta, Egypt.

School of Medicine, Tulane University, New Orleans, Louisiana, USA.

出版信息

J Med Virol. 2021 May;93(5):2740-2768. doi: 10.1002/jmv.26836. Epub 2021 Feb 23.

DOI:10.1002/jmv.26836
PMID:33527440
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8014082/
Abstract

A meta-analysis was performed to identify patients with coronavirus disease 2019 (COVID-19) presenting with gastrointestinal (GI) symptoms during the first and second pandemic waves and investigate their association with the disease outcomes. A systematic search in PubMed, Scopus, Web of Science, ScienceDirect, and EMBASE was performed up to July 25, 2020. The pooled prevalence of the GI presentations was estimated using the random-effects model. Pairwise comparison for the outcomes was performed according to the GI manifestations' presentation and the pandemic wave of infection. Data were reported as relative risk (RR), or odds ratio and 95% confidence interval. Of 125 articles with 25,252 patients, 20.3% presented with GI manifestations. Anorexia (19.9%), dysgeusia/ageusia (15.4%), diarrhea (13.2%), nausea (10.3%), and hematemesis (9.1%) were the most common. About 26.7% had confirmed positive fecal RNA, with persistent viral shedding for an average time of 19.2 days before being negative. Patients presenting with GI symptoms on admission showed a higher risk of complications, including acute respiratory distress syndrome (RR = 8.16), acute cardiac injury (RR = 5.36), and acute kidney injury (RR = 5.52), intensive care unit (ICU) admission (RR = 2.56), and mortality (RR = 2.01). Although not reach significant levels, subgroup-analysis revealed that affected cohorts in the first wave had a higher risk of being hospitalized, ventilated, ICU admitted, and expired. This meta-analysis suggests an association between GI symptoms in COVID-19 patients and unfavorable outcomes. The analysis also showed improved overall outcomes for COVID-19 patients during the second wave compared to the first wave of the outbreak.

摘要

一项荟萃分析旨在确定在第一波和第二波大流行期间出现胃肠道 (GI) 症状的 2019 年冠状病毒病 (COVID-19) 患者,并调查其与疾病结局的关系。截至 2020 年 7 月 25 日,在 PubMed、Scopus、Web of Science、ScienceDirect 和 EMBASE 中进行了系统检索。使用随机效应模型估计 GI 表现的汇总患病率。根据 GI 表现的出现和感染大流行波,对结局进行两两比较。数据以相对风险 (RR)、比值比和 95%置信区间报告。在 125 篇包含 25252 名患者的文章中,有 20.3%的患者出现 GI 表现。厌食症 (19.9%)、味觉丧失/味觉丧失 (15.4%)、腹泻 (13.2%)、恶心 (10.3%)和呕血 (9.1%)是最常见的。约 26.7%的患者粪便 RNA 检测呈阳性,平均在转为阴性前持续病毒脱落 19.2 天。入院时出现 GI 症状的患者发生并发症的风险较高,包括急性呼吸窘迫综合征 (RR=8.16)、急性心脏损伤 (RR=5.36)、急性肾损伤 (RR=5.52)、入住重症监护病房 (RR=2.56)和死亡率 (RR=2.01)。尽管未达到显著水平,但亚组分析显示,第一波受影响的队列住院、通气、入住 ICU 和死亡的风险较高。这项荟萃分析表明 COVID-19 患者的 GI 症状与不良结局之间存在关联。该分析还表明,与疫情第一波相比,第二波 COVID-19 患者的整体结局有所改善。